| 韩楠楠,姜秋颖,李 里,滕 冲,吕艳菊.重组人血管内皮抑制素（恩度）临床机制的研究进展[J].,2019,19(15):2993-2995 |
| 重组人血管内皮抑制素（恩度）临床机制的研究进展 |
| Advance in the Clinical Mechanism of Recombinant Human Endostatin |
| 投稿时间：2018-11-23 修订日期：2018-12-18 |
| DOI：10.13241/j.cnki.pmb.2019.15.044 |
| 中文关键词: 重组人血管内皮抑素 恩度 抗血管生成 凋亡 增敏 |
| 英文关键词: Recombinant human endostatin Endostar Anti-angiogenesis Apoptosis Sensitization |
| 基金项目:国家自然科学基金面上项目（81702464） |
|
| 摘要点击次数: 699 |
| 全文下载次数: 586 |
| 中文摘要: |
| 摘要：重组人血管内皮抑制素(Endostar,恩度)是由我国科学家自主研发的血管内皮抑制素类抗肿瘤药物，是一种大肠杆菌工程菌发酵产品，在临床上常被用作血管靶向治疗，具有靶向精准、低毒性、不产生耐药等优点。恩度能够抗血管生成、诱导肿瘤细胞凋亡，然而只应用抗血管生成药物治疗肿瘤患者，并不能使其得到明显的生存获益，恩度联合化疗/放疗具有增敏作用，从而取得显著的疗效。本文对恩度的作用机制进行探讨，以便于为更好的应用于临床提供有益的参考信息。 |
| 英文摘要: |
| ABSTRACT: Recombinant human endostatin (Endostar) is an endostatin-based antitumor drugs developed independently by Chinese scientists. It is a fermentative product of escherichia coli engineering bacteria and is often used clinically as a vascular targeted therapy, with the advantages of targeted precision, low toxicity, not producing resistance and so on. Endostar is capable of anti-angiogenesis and inducing apoptosis of tumor cells; however, only the application of anti-angiogenic drugs in the treatment of patients with cancer is not able to make them gain significant survival benefit. Endostar combined with chemotherapy/radiotherapy has a sensitizing effect, so as to achieve a one-plus-one-is-greater-than-two effect. This article discusses the mechanism of Endostar, in order to better apply to clinic. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
